BioMark Diagnostics (CSE: BUX; FSE: 20B; OTCQB: BMKDF) has announced the receipt of patent allowances from both the Canadian Intellectual Property Office (CIPO) and the European Patent Office (EPO) for its groundbreaking lung cancer early detection technology.
According to BioMark Diagnostics, its minimally invasive blood test leverages a newly patented algorithm designed to boost screening rates and catch non-small cell lung cancer (NSCLC) at its earliest, most treatable stages. While lung cancer remains a leading cause of mortality worldwide, traditional screening methods often fail to catch the disease before it advances.
In a statement, Rashid Ahmed Bux, CEO and founder of BioMark Diagnostics, commented, “The clinical validation of BioMark’s metabolomics platform is anchored in exceptionally robust data, having already shown immense promise across more than 15,000 blood samples collected throughout Quebec, France, and Germany. The simultaneous allowances from both CIPO and the EPO represent a profound validation of our scientific approach and the clinical significance of our metabolomics platform. These are not peripheral claims; they protect the core metabolic signatures and advanced algorithms driving our screening panel. This vast multi-jurisdictional clinical asset underscores the reliability, reproducibility, and potential of the platform across diverse population groups.”
